Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and
More
First dose of ETC-159 administered in Phase 1B of clinical trials, advancing
Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology
Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against
MoreFirst dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid
MoreAnticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness an increased demand in the
More
Post world war two, the UK had the difficult task ahead of rebuilding cities decimated during the blitz. Asbestos was
More
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer,
More
